Tags

Type your tag names separated by a space and hit enter

Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Graefes Arch Clin Exp Ophthalmol. 2017 Apr; 255(4):691-697.GA

Abstract

PURPOSE

To compare the clinical features and bevacizumab efficacy for macular edema (ME) following branch retinal vein occlusion (BRVO) stratified by baseline visual acuity.

METHODS

This retrospective study included a total 117 eyes from 117 consecutive patients with ME following BRVO, who received PRN intravitreal bevacizumab injection and were followed for more than 6 months. The eyes were categorized into three groups according to baseline best-corrected visual acuity (BCVA) (group A, BCVA <20/200; group B, BCVA ≥20/200 and ≤20/40; group C, BCVA >20/40). Baseline demographics, clinical features, BCVA, and central retinal thickness (CRT) at 1, 3, 6, and 12 months after injection and the number of injections were compared.

RESULTS

Groups A-C included 11, 83, and 23 eyes, respectively. The mean baseline CRT was thickest in group A (810.1, 580.8, and 473.5 μm in groups A-C, respectively; p < 0.001) and the percentage of eyes with macular ischemia increased in the worst BCVA group (45.5, 25.0, and 4.3 % in groups A-C, respectively; p = 0.005). The mean BCVA and CRT improved at 1, 3, 6, and 12 months after treatment compared to baseline values in all groups (all, p < 0.001). The number of injections for 6 months was greater in the worst BCVA group (3.2, 2.3, and 1.9 injections in groups A-C, respectively; p = 0.009).

CONCLUSION

In ME following BRVO, baseline visual acuity correlates with macular ischemia and baseline CRT. Intravitreal bevacizumab treatment results in significant anatomical and functional improvement regardless of baseline visual acuity.

Authors+Show Affiliations

Department of Ophthalmology, Yeungnam University College of Medicine, #170 Hyunchungro, Nam-gu, Daegu, 42415, Korea.Department of Ophthalmology, Yeungnam University College of Medicine, #170 Hyunchungro, Nam-gu, Daegu, 42415, Korea.Department of Ophthalmology, Yeungnam University College of Medicine, #170 Hyunchungro, Nam-gu, Daegu, 42415, Korea. msagong@ynu.ac.kr.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

27796671

Citation

Kim, Mirae, et al. "Efficacy of Intravitreal Bevacizumab for Macular Edema Following Branch Retinal Vein Occlusion Stratified By Baseline Visual Acuity." Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, vol. 255, no. 4, 2017, pp. 691-697.
Kim M, Jeong S, Sagong M. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):691-697.
Kim, M., Jeong, S., & Sagong, M. (2017). Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, 255(4), 691-697. https://doi.org/10.1007/s00417-016-3535-3
Kim M, Jeong S, Sagong M. Efficacy of Intravitreal Bevacizumab for Macular Edema Following Branch Retinal Vein Occlusion Stratified By Baseline Visual Acuity. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):691-697. PubMed PMID: 27796671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. AU - Kim,Mirae, AU - Jeong,Seongyong, AU - Sagong,Min, Y1 - 2016/10/29/ PY - 2016/08/02/received PY - 2016/10/18/accepted PY - 2016/10/12/revised PY - 2016/11/1/pubmed PY - 2017/8/10/medline PY - 2016/11/1/entrez KW - Baseline visual acuity KW - Branch retinal vein occlusion KW - Central retinal thickness KW - Macular edema SP - 691 EP - 697 JF - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie JO - Graefes Arch Clin Exp Ophthalmol VL - 255 IS - 4 N2 - PURPOSE: To compare the clinical features and bevacizumab efficacy for macular edema (ME) following branch retinal vein occlusion (BRVO) stratified by baseline visual acuity. METHODS: This retrospective study included a total 117 eyes from 117 consecutive patients with ME following BRVO, who received PRN intravitreal bevacizumab injection and were followed for more than 6 months. The eyes were categorized into three groups according to baseline best-corrected visual acuity (BCVA) (group A, BCVA <20/200; group B, BCVA ≥20/200 and ≤20/40; group C, BCVA >20/40). Baseline demographics, clinical features, BCVA, and central retinal thickness (CRT) at 1, 3, 6, and 12 months after injection and the number of injections were compared. RESULTS: Groups A-C included 11, 83, and 23 eyes, respectively. The mean baseline CRT was thickest in group A (810.1, 580.8, and 473.5 μm in groups A-C, respectively; p < 0.001) and the percentage of eyes with macular ischemia increased in the worst BCVA group (45.5, 25.0, and 4.3 % in groups A-C, respectively; p = 0.005). The mean BCVA and CRT improved at 1, 3, 6, and 12 months after treatment compared to baseline values in all groups (all, p < 0.001). The number of injections for 6 months was greater in the worst BCVA group (3.2, 2.3, and 1.9 injections in groups A-C, respectively; p = 0.009). CONCLUSION: In ME following BRVO, baseline visual acuity correlates with macular ischemia and baseline CRT. Intravitreal bevacizumab treatment results in significant anatomical and functional improvement regardless of baseline visual acuity. SN - 1435-702X UR - https://www.unboundmedicine.com/medline/citation/27796671/Efficacy_of_intravitreal_bevacizumab_for_macular_edema_following_branch_retinal_vein_occlusion_stratified_by_baseline_visual_acuity_ L2 - https://dx.doi.org/10.1007/s00417-016-3535-3 DB - PRIME DP - Unbound Medicine ER -